HUMULIN
Drug
Lilly USA, LLC
Total Payments
$5.5M
Transactions
39,174
Doctors
5,104
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $21.33 | 2 | 2 |
| 2023 | $58,124 | 3,139 | 1,174 |
| 2022 | $41,712 | 2,582 | 1,123 |
| 2021 | $177,812 | 3,515 | 1,317 |
| 2020 | $183,825 | 268 | 60 |
| 2019 | $633,391 | 5,876 | 1,801 |
| 2018 | $1.5M | 10,953 | 2,382 |
| 2017 | $2.9M | 12,839 | 2,454 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.6M | 2,576 | 46.8% |
| Unspecified | $1.6M | 104 | 28.4% |
| Food and Beverage | $602,379 | 34,823 | 10.9% |
| Consulting Fee | $583,569 | 211 | 10.5% |
| Travel and Lodging | $181,506 | 1,396 | 3.3% |
| Education | $2,840 | 64 | 0.1% |
Payments by Type
General
$4.0M
39,070 transactions
Research
$1.6M
104 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| COMPARATIVE PHARMACOKINETICS AND PHARMACODYNAMICS OF HUMAN REGULAR U 500 INSULIN ADMINISTERED SUBCUTANEOUSLY AS A BOLUS VIA SYRINGE VERSUS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION AND CHARACTERIZATION OF TID AND BID DOSING AT STEADY STATE IN HIGH-DOSE INSULIN TREATED SUBJECTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $795,774 | 1 |
| SAFETY AND EFFICACY OF HUMAN REGULAR U-500 INSULIN ADMINISTERED BY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION VERSUS MULTIPLE DAILY INJECTIONS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS - A RANDOMIZED, OPEN-LABEL, PARALLEL CLINICAL TRIAL | Eli Lilly and Company | $560,183 | 8 |
| DURATION OF ACTION AND PEAK EFFECT OF HIGH DOSE U-500 REGULAR INSULIN IN SEVERELY INSULIN RESISTANT SUBJECTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $156,750 | 0 |
| SAFETY AND EFFICACY OF HUMAN REGULAR U-500 INSULIN ADMINISTERED BY CONTINUOUS SUBCUTANEOUS INSULIN INFUSION VERSUS MULTIPLE DAILY INJECTIONS IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS - A RANDOMIZED, OPEN-LABEL, PARALLEL CLINICAL TRIAL | Eli Lilly Export S.A. Puerto Rico Branch | $57,927 | 2 |
| TWO TREATMENT APPROACHES FOR HUMAN REGULAR U 500 INSULIN THRICE DAILY VERSUS TWICE DAILY IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS NOT ACHIEVING ADEQUATE GLYCEMIC CONTROL ON HIGH DOSE U 100 INSULIN THERAPY WITH OR WITHOUT ORAL AGENTS A RANDOMIZED OPEN-LABEL PARALLEL CLINICAL TRIAL | Lilly USA, LLC | $2,000 | 0 |
Top Doctors Receiving Payments for HUMULIN
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Annette Nitta | — | Honolulu, HI | $1.6M | 102 |
| , M.D.,F.R.C.P.C | Endocrinology, Diabetes & Metabolism | Beaumont, TX | $195,777 | 265 |
| , MD | Endocrinology, Diabetes & Metabolism | Durham, NC | $103,398 | 216 |
| , MD | Endocrinology, Diabetes & Metabolism | Farmington Hills, MI | $100,814 | 168 |
| , MD | Endocrinology, Diabetes & Metabolism | Plano, TX | $100,496 | 108 |
| , D.O | Internal Medicine | Pinellas Park, FL | $97,369 | 234 |
| , MD | Endocrinology, Diabetes & Metabolism | Downey, CA | $96,960 | 161 |
| , M.D | Endocrinology, Diabetes & Metabolism | Philadelphia, PA | $91,741 | 101 |
| , MD | Endocrinology, Diabetes & Metabolism | Southaven, MS | $87,308 | 164 |
| , M.D | Internal Medicine | Rowlett, TX | $79,538 | 121 |
| , MD | Endocrinology, Diabetes & Metabolism | Silver Spring, MD | $77,031 | 164 |
| , M.D | Endocrinology, Diabetes & Metabolism | West Palm Beach, FL | $71,440 | 99 |
| , MD | Endocrinology, Diabetes & Metabolism | Swampscott, MA | $70,680 | 122 |
| , M.D | Endocrinology, Diabetes & Metabolism | Southington, CT | $70,180 | 123 |
| , M.D | Endocrinology, Diabetes & Metabolism | Monroeville, PA | $68,342 | 184 |
| , M.D | Internal Medicine | Hamilton, OH | $68,221 | 86 |
| , MD | Endocrinology, Diabetes & Metabolism | Flemington, NJ | $67,875 | 106 |
| , M.D | Endocrinology, Diabetes & Metabolism | Houston, TX | $63,938 | 151 |
| , M.D | Endocrinology, Diabetes & Metabolism | Austin, TX | $62,376 | 100 |
| , MD | Endocrinology, Diabetes & Metabolism | Houston, TX | $61,433 | 142 |
| , MD | Endocrinology, Diabetes & Metabolism | Peoria, AZ | $59,423 | 127 |
| , MD | Endocrinology, Diabetes & Metabolism | Hershey, PA | $59,404 | 110 |
| , MD | Endocrinology, Diabetes & Metabolism | Snellville, GA | $57,928 | 115 |
| , M.D | Endocrinology, Diabetes & Metabolism | Miramar Beach, FL | $57,801 | 136 |
| , M.D | Endocrinology, Diabetes & Metabolism | Staten Island, NY | $56,137 | 118 |
Ad
Manufacturing Companies
- Lilly USA, LLC $3.9M
- Eli Lilly and Company $1.5M
- Eli Lilly Export S.A. Puerto Rico Branch $94,647
Product Information
- Type Drug
- Total Payments $5.5M
- Total Doctors 5,104
- Transactions 39,174
About HUMULIN
HUMULIN is a drug associated with $5.5M in payments to 5,104 healthcare providers, recorded across 39,174 transactions in the CMS Open Payments database. The primary manufacturer is Lilly USA, LLC.
Payment data is available from 2017 to 2024. In 2024, $21.33 was paid across 2 transactions to 2 doctors.
The most common payment nature for HUMULIN is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.6M, 46.8% of total).
HUMULIN is associated with 5 research studies, including "COMPARATIVE PHARMACOKINETICS AND PHARMACODYNAMICS OF HUMAN REGULAR U 500 INSULIN ADMINISTERED SUBCUTANEOUSLY AS A BOLUS VIA SYRINGE VERSUS CONTINUOUS SUBCUTANEOUS INSULIN INFUSION AND CHARACTERIZATION OF TID AND BID DOSING AT STEADY STATE IN HIGH-DOSE INSULIN TREATED SUBJECTS WITH TYPE 2 DIABETES MELLITUS" ($795,774).